Applied Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases by utilizing targeted drug development that leverages biomarkers and established clinical endpoints. Their approach addresses the urgent need for effective therapies in conditions with high unmet medical needs, such as Classic Galactosemia.

Deep Longevity employs artificial intelligence to analyze biomarkers of aging, enabling accurate evaluations of biological age. This technology provides essential insights into the aging process, facilitating personalized health interventions and advancements in longevity research.

DoctorsForMe.AI utilizes advanced data analytics to evaluate billions of data points on physician expertise, enabling patients with complex conditions to identify the most qualified doctors for their specific diagnoses. This platform addresses the challenge of finding specialized medical care by providing precise recommendations based on clinical excellence and treatment outcomes.

Edifice Health provides the Inflammatory Age® test, a biomarker composite scoring system developed from a decade-long NIH-funded study, to measure and monitor systemic chronic inflammation. This technology enables healthcare providers to identify and manage chronic inflammation, which is linked to age-related diseases and overall health deterioration.

EdiGene develops genome editing technologies, including the LEAPER platform for in vivo RNA base editing and the MAGIC platform for allogeneic cell therapies, to address genetic diseases and cancer. Their high-throughput genome editing screening capabilities enable precise therapeutic interventions, enhancing treatment efficacy and patient outcomes.

Gain Therapeutics is developing pharmacological chaperones using AI-supported 3D structural biology and proprietary physics-based models to target allosteric binding sites on proteins implicated in rare metabolic disorders. Their lead drug candidate, GT-02287, aims to treat GBA-Parkinson’s disease and other neurodegenerative conditions by modulating protein function to restore cellular homeostasis.

Gemelli Biotech develops non-invasive precision diagnostics leveraging microbiome discoveries for gastrointestinal diseases. The company provides clinicians with tools to definitively detect scientifically validated biomarkers for conditions like SIBO and IMO. This enables more optimal treatment strategies for patients suffering from various GI disorders.

Huma provides a business intelligence platform that utilizes generative AI to automate the extraction of insights from diverse healthcare data sources. This technology enables users to conduct complex research queries and generate traceable evidence, enhancing decision-making efficiency in the life sciences sector.

Human Longevity utilizes genomic sequencing and precision diagnostics to create personalized health plans that enhance early detection and treatment of diseases. By analyzing an individual's genetic makeup and health data, the company empowers clients to proactively manage their health and extend their lifespan.

Klevahealth is a health technology company that utilizes data analytics and machine learning to enhance health outcomes across various domains. The platform addresses the challenge of fragmented health data by providing integrated insights that improve patient care and operational efficiency for healthcare providers.

Resonea develops diagnostic tools that utilize advanced sleep monitoring technology to identify sleep disorders more efficiently. Their solutions enhance overall sleep health by providing actionable insights based on real-time data analysis.

The startup develops a digital sleep management platform that integrates with health and wellness applications, utilizing data analytics and wearable devices to enhance sleep quality. By providing evidence-based solutions, the platform enables users to implement lifestyle changes that lead to measurable improvements in sleep health.

X4 Pharmaceuticals develops therapeutics focused on rare immune disorders. The company's pipeline targets the CXCR4 pathway to address unmet medical needs in these patient populations. They are driving progress for individuals living with chronic conditions like neutropenia.